Evidence map›Paper›PMID 37126152›Full record

ArticlePhysical and engineering sciences in medicine2023

Automated detection, delineation and quantification of whole-body bone metastasis using FDG-PET/CT images.

R Nigam, M Field, G Harris, M Barton, M Carolan, P Metcalfe, L Holloway

Open access · hybridAbstract read
In one paragraph

Article in Physical and engineering sciences in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Head-to-head comparative study of [Frontiers in oncology · 2026
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Immune mediated support of metastasis: Implication for bone invasion.Cancer communications (London, England) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

R NigamCentre for Medical Radiation Physics, University of Wollongong, Wollongong, NSW, 2522, Australia. Rashmi.nigam@health.nsw.gov.au.ORCID http://orcid.org/0000-0002-1540-699X
M FieldIngham Institute for Applied Medical Research, Liverpool, NSW, 2170, Australia.
G HarrisChris O'Brien Lifehouse, Camperdown, NSW, 2050, Australia.
M BartonIngham Institute for Applied Medical Research, Liverpool, NSW, 2170, Australia.
M CarolanIllawarra Cancer Care Centre, Wollongong Hospital, Wollongong, NSW, 2500, Australia.
P MetcalfeCentre for Medical Radiation Physics, University of Wollongong, Wollongong, NSW, 2522, Australia.
L HollowayCentre for Medical Radiation Physics, University of Wollongong, Wollongong, NSW, 2522, Australia.
Liverpool Hospital · AUUniversity of Wollongong · AUChris O’Brien Lifehouse · AUThe University of Sydney · AUWollongong Hospital · AU

Funding

National Health and Medical Research Council GNT1132471
6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) patients with the metastatic spread of disease to the bone have high morbidity and mortality. Stereotactic ablative body radiotherapy increases the progression free survival and overall survival of these patients with oligometastases. FDG-PET/CT, a functional imaging technique combining positron emission tomography (PET) with 18 F-fluorodeoxyglucose (FDG) and computer tomography (CT) provides improved staging and identification of treatment response. It is also associated with reduction in size of the radiotherapy tumour volume delineation compared with CT based contouring in radiotherapy, thus allowing for dose escalation to the target volume with lower doses to the surrounding organs at risk. FDG-PET/CT is increasingly being used for the clinical management of NSCLC patients undergoing radiotherapy and has shown high sensitivity and specificity for the detection of bone metastases in these patients. Here, we present a software tool for detection, delineation and quantification of bone metastases using FDG-PET/CT images. The tool extracts standardised uptake values (SUV) from FDG-PET images for auto-segmentation of bone lesions and calculates volume of each lesion and associated mean and maximum SUV. The tool also allows automatic statistical validation of the auto-segmented bone lesions against the manual contours of a radiation oncologist. A retrospective review of FDG-PET/CT scans of more than 30 candidate NSCLC patients was performed and nine patients with one or more metastatic bone lesions were selected for the present study. The SUV threshold prediction model was designed by splitting the cohort of patients into a subset of 'development' and 'validation' cohorts. The development cohort yielded an optimum SUV threshold of 3.0 for automatic detection of bone metastases using FDG-PET/CT images. The validity of the derived optimum SUV threshold on the validation cohort demonstrated that auto-segmented and manually contoured bone lesions showed strong concordance for volume of bone lesion (r = 0.993) and number of detected lesions (r = 0.996). The tool has various applications in radiotherapy, including but not limited to studies determining optimum SUV threshold for accurate and standardised delineation of bone lesions and in scientific studies utilising large patient populations for instance for investigation of the number of metastatic lesions that can be treated safety with an ablative dose of radiotherapy without exceeding the normal tissue toxicity.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsComputersFluorodeoxyglucose F18HumansPositron-Emission TomographyPositron Emission Tomography Computed TomographyTomography, X-Ray ComputedFluorodeoxyglucose F18Bone metastasesImage segmentationMultimodality imagingOligometastasesRadiotherapy treatment planningStereotactic body radiotherapyTumour delineation

Identifiers

PMID37126152
PMCPMC10209253
OpenAlexW4367602110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.